Welcome to our dedicated page for Channel Therapeutics Corporation SEC filings (Ticker: CHRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Channel Therapeutics Corporation (CHRO) provides access to the company’s regulatory disclosures as it transitioned from a clinical-stage biotechnology issuer focused on NaV1.7-based pain therapeutics into Pelthos Therapeutics Inc. under a different trading symbol. These filings document material corporate events, financing arrangements, and structural changes that shaped the company’s evolution.
Among the key documents is a Form 8-K dated July 2, 2025, which describes the closing of a merger pursuant to an Agreement and Plan of Merger involving CHRO Merger Sub, Inc., LNHC, Inc., and Ligand Pharmaceuticals Incorporated. The filing explains that Merger Sub merged with and into LNHC, with LNHC surviving as a wholly owned subsidiary, and that the company’s name was changed from Channel Therapeutics Corporation to Pelthos Therapeutics Inc. It also notes that the company’s shares would trade on the NYSE American under the symbol PTHS.
The same Form 8-K outlines a private placement of Series A Convertible Preferred Stock, referred to as a PIPE financing, including the aggregate amount raised and the basic conversion mechanics into common stock, subject to ownership limits. It further describes a Registration Rights Agreement granting resale registration rights to the investors, and sets out the company’s obligations to file and seek effectiveness of a resale registration statement.
Another section of the 8-K details a Contribution Agreement with a wholly owned subsidiary, Channel Pharmaceutical Corporation, under which the company contributed assets associated with non-opioid, non-addictive therapeutics to alleviate pain, including patents and know-how related to NaV1.7 for systemic chronic pain, eye pain, and post-surgical nerve blocks. This is accompanied by an Intellectual Property Assignment and Assumption Agreement and royalty agreements covering revenue interests in ZELSUVMI and other covered products or technologies.
On Stock Titan, these filings are presented alongside AI-powered summaries that help explain complex transaction structures, preferred stock terms, and royalty arrangements in plain language. Users can quickly understand how financings, mergers, and asset contributions affected CHRO’s capital structure and corporate identity, and how those changes relate to the subsequent Pelthos Therapeutics entity and PTHS ticker.